Healthcare
RxSight, Inc.(RXST)
Live Price
Offline$4.73
+3.05% today
1Y Change
-65.61%
Window
Jun 20, 2025 โ Jun 16, 2026
- Market Cap
- $300.00M
- Revenue Growth
- -3.9%
- EPS Growth
- -33.8%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 20, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RxSight, Inc. (RXST) is a Healthcare stock with a market cap of $300.00M and listed on NASDAQ. The stock last traded around $4.73 and down 65.6% across the available one-year price window (Jun 20, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -3.9%, EPS growth of -33.8%, a dividend yield of 0.0%. What stands out right now is revenue -3.9%, EPS -33.8%, free cash flow +13.6% with operating margin -35.8% and ROIC -16.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RXST price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-3.9% vs +7.6% peer median
Operating Margin
Below sector median
-35.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -3.9% and EPS is at -33.8%, with operating margin around -35.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -14.5% | -18.1% | -24.8% |
2026 Feb 25, 2026 | +34.3% | -10.1% | -10.0% | -25.2% |
2025 Nov 5, 2025 | +79.0% | +3.2% | +20.0% | +49.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RXST
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RXST Max Drawdown
-66.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RXST and SPY.
Company Overview
RxSight, Inc.
NASDAQ Global Market
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
- Leadership
- Ronald Kurtz
- IPO Date
- Jul 30, 2021
- Employees
- 498
- Street Address
- 100 Columbia
- Mailing
- Aliso Viejo, CA, 92656
- Region
- Aliso Viejo, CA, US
- Reporting Currency
- USD
- Investor Line
- 949 521 7830
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.3
- Price/Book
- 1.1
Growth
- Revenue
- -3.9%
- EPS
- -33.8%
- Free Cash Flow
- +13.6%
Profitability
- Gross Margin
- 76.6%
- Operating Margin
- -35.8%
- Net Margin
- -29.0%
- ROE
- -14.0%
- ROIC
- -16.8%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 10.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.